secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2023-12-07T23:59:59+00:00
Accession:  0001683168-23-008696
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma annual meeting: directors elected, reverse split up to 1:40 approved
--------------------------------------------------------------------------------

- All five director nominees elected with >16M votes each; broker non-votes 5.04M.
- Ratification of BF Borgers as auditor approved: 20.1M for, 2.45M against.
- 2023 Equity Incentive Plan approved: 15.9M for, 1.84M against.
- Reverse stock split authorized at ratio between 1:2 and 1:40, board discretion on timing.
- Advisory vote on executive compensation approved; frequency set at every 3 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/0001683168-23-008696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316823008696/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-008696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer